Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Diabetes Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of hyperglycemia. Subjects will also undergo a lumbar puncture at a separate occasion to assess cerebrospinal fluid levels of metabolites.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects with Type 2 Diabetes | Active Comparator | Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination |
|
| Non-Diabetic Obese | Active Comparator | Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals |
|
| Lean, healthy control subjects | Active Comparator | Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brain MRS during hyperglycemic clamp | Other | All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique |
|
| Measure | Description | Time Frame |
|---|---|---|
| Metabolite Measurements by MRS | metabolite levels will be measured by MRS | 4 hours post hyperglycemia |
| Measure | Description | Time Frame |
|---|---|---|
| Hunger Ratings | Hunger will be measured using a visual analog scale | 4 hours post hyperglycemia |
| Satiety Ratings | Satiety will be measured using a visual analog scale |
| Measure | Description | Time Frame |
|---|---|---|
| Cerebrospinal fluid cell count | Metabolite levels will be measure in collected spinal fluid | 2 weeks post MRS testing |
| protein levels | Metabolite levels will be measure in collected spinal fluid |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Sherwin, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06519 | United States |
Not provided
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Analysis of Metabolites in cerebrospinal fluid | Other | All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid |
|
| 4 hours post hyperglycemia |
| Cognitive State | Participants will be asked to complete basic cognitive testing using the mini-mental status exam and the Montreal cognitive assessment | 4 hours post hyperglycemia |
| 2 weeks post MRS testing |